Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60

• Asıl Yazarlar: Alexander Egeberg (Yazar), Jason E. Hawkes (Yazar), Najwa Somani (Yazar), Russel Burge (Yazar), Kyoungah See (Yazar), Gaia Gallo (Yazar), Missy McKean-Matthews (Yazar), Melinda Gooderham (Yazar), George Han (Yazar), April Armstrong (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Adis, Springer Healthcare, 2024-04-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Abstract Introduction Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A, is approved for the treatment of moderate-to-severe plaque psoriasis. Since scalp psoriasis can be burdensome and challenging to treat with non-systemic therapies, this post hoc analysis f...